KIM FOREST Business Summary

KIM FOREST (6645.TW) operates a dual-track business model centered on precision medicine and molecular diagnostics, generating revenue through the distribution of high-end laboratory equipment and the provision of specialized genetic testing services. The company’s primary segments include Biomedical Experiment Products, which supplies PCR equipment, reagents, and automated nucleic acid extraction systems, and Genetic Testing and Analysis Services, which offers whole genome sequencing (WGS), prenatal screening, and oncology monitoring tools like the GoL Life assessment. As a specialized player on the Taiwan Stock Exchange’s Innovation Board, KIM FOREST maintains a niche position by integrating bioinformatics with clinical diagnostics. It competes directly with larger regional biopharmaceutical and diagnostic firms such as Lotus Pharmaceutical (1795.TW), Bora Pharmaceuticals (6472.TW), and Pell Bio-Med Technology (6949.TW), distinguishing itself through its focus on localized genomic data and rapid diagnostic kit development. The company is led by Chairman Pin-Tsung Wu (吳品聰), who co-founded the firm in 2004 and has been instrumental in its transition from a medical equipment wholesaler to a comprehensive biotechnology provider. The executive team includes General Manager Wen-Ming Yang (楊文明), who oversees operational strategy and investor relations, and Chief Technology Officer Tao-Peng Chen (陳道鵬), a key figure in the firm’s R&D efforts for cancer and infectious disease detection. Notable leadership also includes Director Hui-E Chen (陳惠娥), a major shareholder and former CEO with extensive experience in biomedical commercialization. The board is supported by institutional and private investors, including Gao Yu Enterprise, reflecting a stable ownership structure focused on long-term expansion within the precision medicine markets of Taiwan, China, and the United States.